ArticleBlood advances2024

Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial.

Adriano Venditti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.